Sign up to save your podcasts
Or
Share Biotech Bros
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Biotech Bros
Biotech Bros episodes
- A Lackluster JPM and a Troubling future for Fate Therapeutics
This week on the podcast Agustin discusses the excitement for 2023 in biotech investing and highlights some key tailwinds that could provide a return to positive returns for investors. He also discusses the rather lackluster JPM conference and highlights the troubles plaguing Fate Therapeutics and other natural killer cell therapy companies.
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
57 min - A Therapy for NASH, Another Alzheimer's Competitor, and Reflections on 2022
This week on the podcast Agustin discusses Madrigal Pharmaceuticals' recent phase III win in NASH, he highlights another monoclonal antibody in the Alzheimer's space, and provides a reflection on the markets in 2022.
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
1 hr 3 min - Questions around the Tesla of Biotech, Amgen buying Horizon, and Mirati in the Dumps
This week on the podcast Agustin shares some recent action and news in the biotech market from failed acquisitions to a pending purchase to questions around a synthetic biology powerhouse.
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
1 hr 1 min - Setting the Record Straight with $LPTX and $AFMD
This week on the podcast Agustin provides updates on key readouts from Affimed and Leap Therapeutics in particular setting the record straight for their recent data readouts. In addition he shares some exciting news regarding a new initiative!
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
1 hr 5 min - PRIME Medicines Big IPO and an attractive play in the NASH space
This week on the podcast Agustin talks about the recent fluctuations within the market, the 300 million dollar IPO of a big time base editing gene therapy company, and highlights an interesting play within the NASH space.
All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...Listen on: Apple Podcasts Spotify
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
57 min - Behind the Scenes of an IPO: Interview with TC Biopharm
This week on the podcast Agustin sits down with the Bryan Kobel CEO of TC Biopharm. Bryan spent years leading healthcare investment banking at EF Hutton and the Alberleen Group before switching roles and joining TC Biopharm.
All Business. No Boundaries.
On this podcast we discuss a host of topics from TC Biopharm's IPO earlier in the year, to the state of biotech and equity markets, to the transformative technology behind TC Biopharm.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...Listen on: Apple Podcasts Spotify
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
54 min - A Potential Recession and Another Alzheimer's Drug from Biogen
This week on the podcast Agustin talks recent macroeconomic trends and their implications on the stock market and biotech specifically, highlights the positive phase 3 data for another Biogen Alzheimer's drug, and shares the recent approval for Amylyx Pharmaceuticals and their 6-figure a year drug for ALS.
All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...Listen on: Apple Podcasts Spotify
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
53 min - Good News for $AMLX and Covid Booster Approvals with only Mouse Data?
This week on the podcast Agustin discusses news around Amgen's big 1L data drop for its KRAS inhibitor Lumakras, the shifting perceptions for $AMLX and what could become an approval for their ALS therapy, and the shortsightedness of the FDA and CDC around approving covid boosters based only on mouse data!
All Business. No Boundaries.
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...Listen on: Apple Podcasts Spotify
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
53 min - More Data for The Most Undervalued Biotech
This week on the podcast Agustin highlights the recent data update from this small biotech company. The company is up already 119% in the past month and their most recent data may convince big pharma that an acquisition is warranted. Additionally, he discusses the one biotech company that the whole street should love: Leap Therapeutics
All Business. No Boundaries.
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...Listen on: Apple Podcasts Spotify
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
46 min - Things Looking Green for $XBI and Alnylam Pharmaceuticals
This week on the podcast Agustin addresses the flurry of acquisitions that have precipitated in the recent weeks as well as the growing excitement in the sector as indices rebound from their May lows. He also highlights the recent data from Alnylam Pharmaceuticals regarding their therapy for ATTR-CM and the increasingly competitive market that is developing.
All Business. No Boundaries.
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...Listen on: Apple Podcasts Spotify
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
56 min
About Biotech Bros
From the publisher's feed
Discussing the world of biotech!